The human papillomavirus (HPV) E7 protein is one of only two viral proteins that remain expressed in HPVassociated human cancers. HPV E7 proteins share structural and functional similarities with oncoproteins encoded by other small DNA tumor viruses such as adenovirus E1A and SV40 large tumor antigen. The HPV E7 protein plays an important role in the viral life cycle by subverting the tight link between cellular dierentiation and proliferation in normal epithelium, thus allowing the virus to replicate in dierentiating epithelial cells that would have normally withdrawn from the cell division cycle. The transforming activities of E7 largely re¯ect this important function. Oncogene (2001) 20, 7888 ± 7898.
Introduction
The continually growing list of human papillomaviruses (HPVs) now encompasses more than 100 distinct types. Like all papillomaviruses, HPVs possess a pronounced tropism for squamous epithelial cells. Despite their similar overall genomic make-up, dierent HPVs infect epithelia at speci®c anatomic locations. Approximately 30 HPV types preferentially infect the anogenital tract mucosa. These HPVs are also detected in the oral mucosa, and are further classi®ed intò high-risk' and`low-risk' types based on the clinical prognosis of the lesions that they cause. Low-risk HPVs are associated with benign warts, whereas highrisk HPVs cause lesions that have a propensity for malignant progression. Even though the rate of carcinogenic progression is relatively low, infections with high-risk HPVs account for almost all human cervical cancers, a leading cause of cancer death in younger women worldwide (reviewed in zur Hausen, 1996) . Moreover, approximately 20% of oral cancers, particularly oropharyngeal carcinoma in patients that often lack risk factors such as alcohol and tobacco abuse, are also associated with high-risk HPVs (Gillison et al., 2000) .
The E7 protein was the ®rst oncogene of high-risk HPVs to be discovered. HPV E7 induces transformation of rodent ®broblast cell lines (Bedell et al., 1989; Phelps et al., 1988; Vousden et al., 1988; Yasumoto et al., 1986) , can cooperate with the ras oncogene to transform primary rodent ®broblasts (Matlashewski et al., 1987; Phelps et al., 1988) , and in combination with E6 extend the life span of primary human cells (Hawley-Nelson et al., 1989; Hudson et al., 1990; MuÈ nger et al., 1989) . HPV E7 proteins are small, rather acidic polypeptides composed of approximately 100 amino acid residues. Their amino termini contain a region of sequence homology to a small portion of conserved region 1, and the entire conserved region 2 of adenovirus (Ad) E1A and related sequences in the large tumor antigens (T Ag) of polyomaviruses, including SV40 (Figge et al., 1988; Phelps et al., 1988; Vousden and Jat, 1989) . The carboxyl termini contain a zinc-binding domain consisting of two copies of a Cys-X-X-Cys sequence motif separated by 29 amino acid residues (Barbosa et al., 1989; McIntyre et al., 1993) . This portion of E7 can act as a dimerization/ multimerization domain (Clemens et al., 1995; Clements et al., 2000; McIntyre et al., 1993) . Intriguingly, the HPV E6 oncoprotein consists of two tandem copies of this domain, and it has been speculated that E6 and E7 may have evolved from a common ancestral precursor (Cole and Danos, 1987) . As with other DNA tumor viral oncoproteins, the human genome contains no closely related cellular homologues of E7 (see Figure 1) . HPV E7 proteins are phosphoproteins (Smotkin and Wettstein, 1987) and contain a casein kinase consensus phosphorylation site in their amino terminal portion (Barbosa et al., 1990 ). An additional carboxyl terminal phosphorylation site has been described but the protein kinase that targets this site is unknown . Immuno¯uorescence studies have shown that HPV E7 proteins are predominantly nuclear (Green®eld et al., 1991; Sato et al., 1989; SmithMcCune et al., 1999) . They lack a prototypical nuclear localization sequence and the nuclear import mechan-ism of these proteins has not yet been delineated. A number of non-nuclear cellular target proteins of E7 have been described in recent years (reviewed in and hence it is possible that at least under some conditions, a certain fraction of E7 may reside in the cytoplasm (Smotkin and Wettstein, 1987) . E7 has also been detected at nucleolar structures in some cell types (Zatsepina et al., 1997) . The relatively low steady-state levels of E7 in cervical cancer cells, the lack of a set of sensitive antibodies that recognize independent epitopes, and the tendency of E7 to leak out of the nucleus during biochemical fractionation of cells has complicated the interpretation of such studies. The low cellular steadystate level of E7 is a consequence of its relatively short half-life of less than 2 h (Smotkin and Wettstein, 1987) . HPV-16 E7 is a target of ubiquitin-dependent proteolysis but, unlike many other proteins that are turned over by this mechanism, the conjugation of ubiquitin is independent of internal lysine residues and occurs at the terminal amino group (Reinstein et al., 2000) .
HPV E7 and the viral life cycle
Tumorigenic progression of high-risk HPV-associated lesions is almost always accompanied by the physical integration of the viral genome into a host chromosome, and hence it is not a manifestation of the normal viral life cycle. Nevertheless, the oncogenic activities of high-risk human papillomavirus E7 proteins likely re¯ect their function during the viral life cycle. The replicative life cycle of HPVs is tightly coupled to the dierentiation state of the host keratinocyte. The initial infection with HPV involves undierentiated, basal keratinocytes. High copy number viral genome ampli®cation, expression of the late viral capsid proteins and the full vegetative life cycle, however, take place speci®cally in the dierentiated upper epithelial strata. Since HPVs do not fully lyse their host cells, virus particles are deposited within the epithelial squames that are constantly shed. Constrained by their small genome size HPVs do not encode the full complement of functions that are necessary for their replication, and consequently the host cell's DNA synthesis machinery needs to be procured for this purpose (reviewed in Stubenrauch and Laimins, 1999) . In normal epithelia, cellular dierentiation is tightly linked to withdrawal from the cell division cycle. Cellular DNA synthesis no longer occurs in dierentiated epithelial cells and thus, they are not inherently capable of supporting viral replication. The experimental ®nding that expression of HPV E7 can uncouple dierentiation and proliferation and hence, retain dierentiating keratinocytes in a DNA replication competent state has been central to our understanding of the biological activities of E7 (Cheng et al., 1995; Woodworth et al., 1992) .
The expression of a number of rate-limiting factors for cellular DNA synthesis including DNA polymerase a, enzymes involved in nucleotide biosynthesis such as dehydrofolate reductase and thymidine kinase, and cyclin E, an activator of cyclin dependent kinase (CDK) 2 that is rate limiting for S phase progression is controlled by the E2F family of transcription factors controls (reviewed in Dyson, 1998) . E2F derived its designation from the initial description as a cellular factor activated by the Ad E1A protein to induce expression of the viral E2 gene (Kovesdi et al., 1986) . The HPV E7 protein can also activate the Ad E2 promoter even though its own viral regulatory circuits do not appear to be dependent on E2F activation (Phelps et al., 1988) . E2F-1 was cloned as a pRBassociated factor (Helin et al., 1992; Kaelin Jr et al., 1992) and linked the ability of viral oncoproteins to interact with pRB and activate E2F-responsive promoters. In normal cells, E2F transcriptional activity is regulated by cyclin/cdk-dependent phosphorylation of pRB. This causes disruption of the pRB/E2F transcriptional repressor complex and transcriptional activation of E2F-responsive promoters. Several additional E2F family members have now been cloned. The E2F transcription factor is a heterodimer consisting of an E2F subunit bound to a DP family member (Bandara et al., 1993; Helin et al., 1993) . E2F-DP heterodimers function as DNA-binding transcriptional activators. The pocket proteins pRB, p107 and p130 act as important regulatory subunits of these complexes. Binding of the pocket proteins not only masks the transcriptional activation domain of E2F/DP Figure 1 Interaction of cellular proteins with HPV E7. A schematic representation of the HPV-16 E7 domain structure is shown. CR1 HD and CR2 HD denote the homology domains to conserved regions 1 and 2 of the Adenovirus E1A protein, respectively. CR2 HD contains the core pRB binding domain (LXCXE) and a consensus sequence for casein kinase II phosphorylation (CKII). The metal binding domain consisting of two C-X-X-C sequences in the carboxyl terminus is also shown. Gray bars indicate biochemical and/or functional interaction domains with each of the cellular proteins that are listed. See text for details and references complexes but the approximation of the transcriptional repressor domain encoded by the pocket proteins converts E2F-DP complexes into transcriptional repressors that actively restrict S phase entry (Luo et al., 1998; Weintraub et al., 1992; . Upon cdkdependent phosphorylation late in G1, these complexes dissociate and E2F is converted into a transcriptional activator that stimulates S phase entry. The perturbation of this delicate regulatory network by HPV E7 and other viral oncoproteins re¯ects the necessity of these viruses to maintain their host cell in a state that is conducive for viral replication (Figure 2 ). It is important to re-emphasize that HPVs need to ensure that their host cells still undergo some aspects of cellular dierentiation since their life cycles, in particular the early to late switch and the synthesis of viral capsid proteins, depends on cellular dierentiation cues. Hence, these viruses must uncouple the processes of cellular dierentiation and proliferation. The ability of E7 to inactivate the cyclin dependent kinase inhibitors (CKIs) p21 CIP1 (Funk et al., 1997; Jones et al., 1997a) and p27 KIP1 (Zerfass-Thome et al., 1996) may be particularly relevant for this function. Several studies in mouse and human keratinocytes have shown that as in other systems (Guo et al., 1995; Steinman et al., 1994) , p21
CIP1 plays an important role in coupling cell cycle arrest and dierentiation in keratinocytes (Alani et al., 1998; Di Cunto et al., 1998; Missero et al., 1996) . The steady-state levels of p21 CIP1 increase during cellular dierentiation resulting in inactivation of cdk2 activity and growth arrest. This increase of p21 CIP1 during human keratinocyte dierentiation is independent of p53 and involves both transcriptional and non-transcriptional mechanisms (Alani et al., 1998) . Intriguingly, p21
CIP1 levels are further augmented in E7-expressing cells. This increase is a consequence of protein stabilization (Jian et al., 1998; Jones et al., 1999; Noya et al., 2001) . Despite higher p21 CIP1 levels, cdk2 remains active in E7-expressing cells (Funk et al., 1997; Jones et al., 1997a; Ruesch and Laimins, 1997) . Even though some studies showed that those E7 expressing cells with the highest levels of p21 CIP1 expression do not express PCNA, and hence do not appear to undergo cellular DNA synthesis (Jian et al., 1998) , it is likely that such cells are more conducive for viral DNA synthesis than their uninfected counterparts.
The ability of E7 to abrogate the inhibitory activities of CKIs such as p21 CIP1 and p27
KIP1
, in combination with the sustained inactivation of E2F-pocket protein repressor complexes results in enhanced expression of cellular proteins that are rate-limiting for cellular DNA synthesis and importantly contribute to the function of E7 as a viral replication competence factor ( Figure 2 ). Consistent with this notion, it was shown that expression of E7 and its ability to subvert cellular targets such as pRB are indispensable for HPV replication and the full viral life cycle (Flores et al., 2000; Thomas et al., 1999) .
The retinoblastoma tumor suppressor and the related pocket proteins' are major cellular targets of high-risk HPV E7 proteins
The HPV E7 oncoprotein shares a small block of amino acid sequence similarity with Ad E1A and SV40 T Ag (Figge et al., 1988; Phelps et al., 1988; Vousden and Jat, 1989) . This sequence contains an LXCXE motif, the canonical binding site for pRB and the related pocket proteins p107 and p130 (Lee et al., 1998) (Figure 1 ). As outlined earlier, the pocket proteins regulate the transcriptional activities of E2F transcription factors. The initial model was that E7, like SV40T Ag and Ad E1A, would stoichiometrically interact with pRB and the pocket proteins p107 and p130, thereby displacing and aberrantly activating E2F. According to this model, the constitutive transcriptional activation (or de-repression) of E2F would result in the functional inactivation of pRB thus contributing to cellular transformation. In support of this model, it was shown that mutations in high-risk HPV E7 that interfere with pRB binding impinge on the cellular transformation activity (reviewed in Phelps et al., 1992) , and similarly, that enhancing the pRB binding eciency of low-risk HPV-6 E7 could increase its transforming activity (Heck et al., 1992; Sang and Barbosa, 1992) . However, Figure 2 Relaxation of G1/S cell cycle control by HPV E7. High-risk HPV E7 proteins destabilize pRB thus abrogating the pRB/E2F transcriptional repressor complex. This causes increased expression of E2F responsive cell cycle regulators such as cdc25A, cyclin E, and through an indirect mechanism, cyclin (a) Other E2F targets are replication enzymes such as dehydrofolate reductase (DHFR), thymidine kinase (TK) and DNA polymerase a (pola). Cells expressing E7 contain higher amounts of the p53 tumor suppressor, which remains transcriptionally inert. HPV-16 E7 can also interact with the cyclin-dependent kinase inhibitors p21 CIP1 , a transcriptional target of p53, and p27
. These molecules are also activated by other growth inhibitory stimuli including transforming growth factor b (TGFb), tumor necrosis factor a (TNFa). Since HPV replication occurs in dierentiated epithelial cells that have normally withdrawn from the cell division cycle, these activities of E7 contribute to the viral life cycle by creating and/or maintaining a cellular milieu that is conducive for viral replication. See text for details several lines of evidence suggested that this model needed to be revised. E2F does not contain an LXCXE motive and binds to a dierent region of pRB than HPV E7 (Dick et al., 2000; Huang et al., 1993; . Additional sequences in the carboxyl terminal dimerization domain of E7 are required for disruption of E2F/pRB complexes (Helt and Galloway, 2001; Huang et al., 1993; Wu et al., 1993) . Some chimeric E7 proteins with the carboxyl terminus replaced with structurally related HPV E6 derived domains were impaired for disruption of E2F/pRB complexes but remained transformation competent (Braspenning et al., 1998; Mavromatis et al., 1997) . These results suggested that the ability of E7 to disrupt pRB/E2F complexes and cellular transformation are not necessarily linked. In some cell types the transformation de®cient low-risk HPV-6 E7 protein can eciently transactivate E2F-dependent promoters (Armstrong and Roman, 1997; MuÈ nger et al., 1991) , suggesting that cellular transformation and the ability of E7 to transcriptionally activate E2F-dependent promoters are not strictly correlated. Most strikingly, however, the E7 protein encoded by the cutaneous lowrisk HPV-1 can interact with pRB as eciently as HPV-16 E7 and potently activates E2F-responsive promoters, yet is transformation negative (Ciccolini et al., 1994; Schmitt et al., 1994) . In addition several nontransforming HPV-16 E7 mutants retain the ability to interact with pRB and eciently activate transcription of E2F-responsive promoters (Banks et al., 1990; Brokaw et al., 1994; Edmonds and Vousden, 1989; Jewers et al., 1992; Phelps et al., 1992) . Some of these mutants are within the extreme amino terminal conserved region 1 homology domain of E7. Other mutants within the casein kinase II consensus phosphorylation site immediately adjacent to the pRB binding site (Firzla et al., 1991) as well as the carboxyl terminus also have defects in cellular immortalization and transformation independent of pRB binding (Helt and Galloway, 2001; Jewers et al., 1992) . The carboxyl terminus has been implicated in the binding of many cellular proteins (see Figure 1) . The phosphorylation state of the CKII site contributes to the binding of the TATA box binding protein TBP (Massimi and Banks, 1997; Phillips and Vousden, 1997) and F-actin (Rey et al., 2000) but, somewhat surprisingly, it does not modulate pocket protein binding to the immediately adjacent LXCXE motif.
Binding to high-risk HPV E7 results in the destabilization of pRB and the related pocket proteins p107 and p130 Boyer et al., 1996; Giarre et al., 2001; Gonzalez et al., 2001; Helt and Galloway, 2001; Jones and MuÈ nger, 1997; SmithMcCune et al., 1999) . Whereas the exact biochemical mechanism remains elusive, inhibitors of the 26S proteasome interfere with E7-mediated pRB degradation (Boyer et al., 1996; Gonzalez et al., 2001) . Since HPV-16 E7 can interact with the S4 subunit of the 26S proteasome it was proposed that HPV E7 might induce pRB degradation by directly targeting it to the proteasome ). An S4 binding de®cient HPV-16 E7 mutant, however, can still eciently destabilize pRB (Gonzalez et al., 2001) suggesting other mechanisms of action. HPV-16 E7-induced pRB degradation is also independent of ubiquitin-mediated degradation of E7, as an amino terminally tagged proteasome-resistant version of E7 can still eciently target pRB for degradation (Gonzalez et al., 2001) . Binding of E7 to pRB is necessary for pRB degradation, but additional sequences also contribute to E7-mediated pRB degradation. In particular, transformation-impaired E7 mutants within the amino terminal conserved region 1 homology domain of E7 as well as within the casein kinase II phosphorylation sequence are defective for pRB degradation (Gonzalez et al., 2001; Helt and Galloway, 2001; Jones and MuÈ nger, 1997; Jones et al., 1997b) . Similarly, the transformation de®cient cutaneous low-risk HPV-1 E7 protein that eciently binds pRB is unable to destabilize pRB (Giarre et al., 2001; Gonzalez et al., 2001) . Hence, the ability of E7 to induce pRB degradation correlates more tightly with cellular transformation than pRB binding. The capacity of E7 to destabilize the pocket proteins pRB, p107 and p130 is not shared by the related Ad E1A and SV40 T Ag oncoproteins. This exempli®es the dierent strategies that these viral oncoproteins have developed to inactivate these important cellular regulatory proteins. Whereas HPV E7, Ad E1A and SV40 T Ag each contain the core pRB binding sequence LXCXE, Ad E1A has an additional amino terminal low-anity pRB-binding domain , and SV40 T Ag contains an amino terminal J-domain (Kelley and Georgopoulos, 1997), a signature sequence of the hsp40 family of chaperone proteins. The SV40 T Ag J-domain does not directly contribute to pRB binding but is necessary for T Ag-mediated inactivation of pRB (Sheng et al., 1997; Zalvide et al., 1998) . The J-domain is also necessary for the ability of T Ag to inactivate and alter the abundance of some phosphorylated p107 and p130 species (Stubdal et al., 1996 (Stubdal et al., , 1997 . Interestingly the HPV-16 E7 has been reported to interact with a cellular dnaJ protein, hTid (Schilling et al., 1998) . This gene, the human homologue of the Drosophila tumor suppressor lethal(2) tumorous imaginal discs, l(2)tid, encodes two dierentially spliced variants that have opposing eects on the execution of apoptosis. The proteins contain mitochondrial targeting signals and localize mostly to the mitochondrial matrix (Syken et al., 1999) . Some studies have suggested that under some conditions, a fraction of Tid proteins may reside in non-mitochondrial locations (Trentin et al., 2001) and the HPV E7 protein may presumably target this population. There is evidence suggesting that E7-mediated activation of E2F-responsive promoters indeed involves a J-domain function (Sheng et al., 1997) .
The ability of HPV E7 to induce the proteolytic elimination of the pocket proteins is a highly ecient strategy for a single E7 polypeptide to inactivate multiple molecules of cellular target proteins. The relatively low levels of E7 that are expressed in HPV-infected lesions and transformed cells may necessitate this enzymatic action of pocket protein inactivation. In addition, this mechanism ensures that E7 can subvert the entire spectrum of biological activities of the pocket proteins including those related to cellular dierentiation and senescence that are independent of E2F (Sellers et al., 1998) . It should also be noted that this unique mechanism of E7-mediated pRB inactivation might hold promise for the design of small molecule inhibitors of this enzymatic process.
Subversion of p53 functions by HPV E7
Like many other DNA tumor viruses that target pRB, high-risk HPVs also encode a second function, E6, which subverts p53 function by inducing its rapid proteasomal degradation (Schener et al., 1992) . Hence, the ®nding that HPV E7 could interfere with the ability of p53 to induce G1 growth arrest in response to cellular insults was quite surprising (Demers et al., 1994a; Hickman et al., 1994; Slebos et al., 1994; Vousden et al., 1993) . Multiple mechanisms likely contribute to this activity of E7, including E2F-mediated aberrant expression of cyclins E and A (Hickman et al., 1994) and cdc25A (Katich et al., 2001) , inactivation of the p53-responsive CKI p21 CIP1 (Funk et al., 1997; Jones et al., 1997a) , and the decreased cellular steady-state levels of pRB (Figure 2) .
In normal cells the p53 tumor suppressor protein has a short half-life due to rapid proteasomal degradation mediated by the ubiquitin ligase mdm2 (Honda et al., 1997) . HPV E7 expressing cells contain increased steady-state levels of p53 (Demers et al., 1994b) and the half-life of p53 is increased in E7 expressing cells, suggesting that E7 may perturb p53 degradation . It was reported that the p53-speci®c ubiquitin ligase mdm2 is not as eciently bound to p53 in E7 expressing cells as in normal cells (Seavey et al., 1999) . Given the ability of E7 to activate E2F-responsive promoters, it has been postulated that the increased p53 levels in E7 expressing cells may be mediated by E2F-mediated transcriptional induction of p14 ARF , an inhibitor of mdm2-mediated p53 degradation Zhang et al., 1998) . Interestingly, however, expression of E7 does not cause a rapid increase of p14 ARF , and E7-mediated p53 stabilization is also observed in ARFde®cient mouse embryo ®broblasts (Seavey et al., 1999) . These results suggest that alternative mechanisms contribute to the ability of E7 to stabilize p53. Nevertheless, it has been demonstrated that the normal physiological pathway of mdm2-mediated p53 turnover is not active in high-risk HPV E6/E7 expressing cervical carcinoma cell lines and the rapid turnover of p53 in these cell lines is solely a function of the E6/ E6AP p53-speci®c ubiquitin ligase complex (Hengstermann et al., 2001) .
The steady-state levels of the CKI p21
CIP1
, a transcriptional target of p53, are similarly augmented in E7-expressing cells (Thomas and Laimins, 1998) . This increase, however, is mostly a consequence of protein stabilization and is not due to transcriptional induction (Jones et al., 1999; Noya et al., 2001) . In fact, it appears that despite its increased levels, the transcriptional activity of p53 is disturbed in E7-expressing cells. Consistent with this ®nding, it was shown that E7 could interfere with the activation of p53-responsive reporter constructs in transient transfection assays (Massimi and Banks, 1997) . This has been linked to the ability of E7 to interact with TBP (Massimi and Banks, 1997; Phillips and Vousden, 1997) . Like adenoviruses, high risk HPVs may have developed multiple mechanisms to modulate p53 function.
Abrogation of cytostatic activities of cytokines by HPV E7
Transforming growth factor b (TGF-b) is an important cytokine that restricts the growth of epithelial cells. The majority of squamous cell carcinomas including cervical cancer cell lines, however, are resistant to growth suppression by TGF-b (reviewed in Polyak, 1996) . The high-risk HPV E7 can abrogate the growth inhibitory activities of TGF-b (Pietenpol et al., 1990) . The acquisition of TGF-b resistance in HPV expressing keratinocyte cell lines, however, is more complicated than predicted from the initial study. TGF-b treatment leads to decreased expression of the HPV E6 and E7 oncoproteins. As a consequence, freshly derived HPV containing epithelial cell lines remain sensitive to TGFb (Creek et al., 1995) . In a keratinocyte based in vitro progression model, TGF-b resistance occurs in parallel with the acquisition of resistance to dierentiation cues such as retinoic acid, and is characterized by the loss of transcriptional sensitivity of HPV oncogene expression toward TGF-b . The molecular targets of HPV E7 that result in TGF-b resistance are largely unknown but loss of TGF-b receptor 1 expression has been reported . It is conceivable, however, that the ability of HPV E7 to inactivate the CKIs p21 CIP1 and p27
KIP1
, which have both been implicated in TGF-b mediated growth inhibition (Datto et al., 1995; Elbendary et al., 1994; Polyak et al., 1994 ) may contribute to this activity (Figure 2 ). TGF-b can also induce expression of p15 ink4B , a p16 ink4A -related cdk4/cdk6 speci®c CKI (Hannon and Beach, 1994) . Given the similarities of these two CKIs it is possible, that like p16 ink4A , p15
INK4B
-induced growth suppression requires functional pocket proteins pRB, p107 and p130 (Bruce et al., 2000) . Hence as predicted by the original study, the ability of E7 to target pocket protein functions may contribute to the induction of the TGF-b resistance phenotype (Pietenpol et al., 1990) .
Similarly, HPV containing cervical carcinoma cell lines are also resistant to the cytostatic activity of tumor necrosis factor a (TNF) (Villa et al., 1992) . TNF is produced by cytotoxic T cells and is an important mediator of immune response to viral infection. TNF induces G1 growth arrest and cellular dierentiation in normal keratinocytes. Like in other scenarios this is accompanied by p53-independent induction of p21 CIP1 (Figure 2 ). This cytostatic eect of TNF is keratinocyte-speci®c and is not observed in ®broblasts. Moreover, other TNF-related cytokines such as Fas ligand and TNF-related apoptosis inducing ligand (TRAIL) have no cytostatic eects. HPV E7-expressing keratinocytes are impervious to TNF and continue to proliferate in the presence of this cytokine. Mutagenic analyses suggest that the ability of E7 to subvert TNFmediated growth arrest correlates with the potential of E7 to inactivate pocket protein functions . TNF treatment can also lead to apoptosis when administered in combination with the protein synthesis inhibitor cycloheximide. HPV E7 expressing keratinocytes have an increased propensity to undergo TNF mediated apoptosis Stoppler et al., 1998) , whereas in normal human ®broblasts, expression of E7 obstructs TNF-induced caspase 8 activation and apoptosis (Thompson et al., 2001) .
Interferons (IFNs) are important cytostatic cytokines that are produced in response to viral infections. HPV E7 can interact with p48, the DNA binding component of ISGF-3 and prevent its nuclear translocation upon IFN-a stimulation (Barnard and McMillan, 1999; Barnard et al., 2000) . This may severely compromise cellular signaling by IFN-a. In addition, E7 can also interact with and inactivate the IFN-g induced transcription factor IRF-1 that in turn can regulate the expression of IFN-b Perea et al., 2000) . Sequences in the amino terminal CR1 and CR2 homology domains as well as the carboxyl terminus of E7 which can interact with the histone deacetylase Mi2b, (Brehm et al., 1999) , the forkhead transcription factor MPP2 (Luscher- Firzla et al., 1999) and AP1 (Antinore et al., 1996) contribute to the abrogation of IRF-1 transcriptional activity . It is interesting to note that HPV E7 has also been reported to interact with the 110 kDa TBP-associated factor (TAF110). The sequences of E7 that are required for this interaction have not been mapped in detail but TAF110 binding may contribute to the ability of E7 to modulate transcription (Mazzarelli et al., 1995) .
In addition, E7 can interact with insulin like growth factor binding protein-3 (IGFBP-3). This interaction is mediated by the carboxyl terminal domain of E7 and decreases the abundance of IGFBP-3 . IGFBP-3 is a transcriptional target of p53 and may limit the cellular availability of IGFs, which are important cellular survival factors.
Eects of HPV E7 on cellular metabolism
A series of intriguing experiments has suggested that expression of high risk HPV E7 proteins can directly induce fundamental cellular metabolic alterations that also commonly occur in a variety of cancer cell lines. The glycolytic enzyme M2 pyruvate kinase (PK) can adopt a highly active tetrameric form with a high anity for phosphoenolpyruvate, and a dimeric form with a low anity for this crucial metabolite. Like many cancer cell lines, HPV E7 transformed cell lines contain increased amounts of the dimeric form of M2 PK and show a decreased glycolytic¯ux. Dimeric M2 PK persists in E7 expressing cells despite high levels of fructose 1,6 bisphosphate that normally stimulate the formation of the high anity, tetrameric form. Yeast two hybrid analyses revealed an interaction between E7 and M2 PK, and it has been hypothesized that E7 may directly disrupt the normal metabolic regulation of M2 PK (Mazurek et al., 2001; Zwerschke et al., 1999) . In addition, HPV-16 E7 has also been reported to interact with and allosterically activate a-glucosidase . Activation of this enzyme results in the depletion of intracellular glycogen stores, similar to what has been observed in human cancers (Bannasch et al., 1997) including cervical lesions (Pedersen, 1975) . The activation of these enzymes in E7 expressing cells may drive cellular hyperproliferation or alternatively represent a consequence of the altered energy requirements of rapidly growing transformed cells.
An additional physiological hallmark of transformed cells is an increase of the intracellular pH. Expression of HPV E7 in NIH3T3 cells results in intracellular alkalinization mediated by stimulation of Na + /H + exchanger activity. Most interestingly, inhibition of the E7-induced cytoplasmic alkalinization by several methods interfered with the development of cellular characteristics of transformed cells such as hyperproliferation, growth in low serum or soft agar containing growth media, and alterations in glycolytic metabolism. The results suggest that intracellular alkalinization represents an early and important step that contributes to cellular transformation. The biochemical pathways through which E7 contributes to intracellular alkalinization, however, are unknown (Reshkin et al., 2000) .
A role for HPV E7 in carcinogenic progression ± E7 is a mitotic mutator
One of the de®ning characteristics of a tumor is its genomic plasticity. This is in part a consequence of the loss of cell cycle checkpoint functions thus allowing cells with genomic alterations to remain in the replicative pool. The p53 tumor suppressor plays an important role by integrating the responses to multiple cellular stress signals including those generated by DNA damage or caused by aberrant DNA synthesis that is incongruent with surrounding cells. Activation of p53 induces a program of cellular growth arrest, presumably to allow for DNA to be repaired. Under some circumstances p53 triggers apoptosis, a hardwired cell death program. The p53 pathway is inactivated in the majority of human tumors (Hsieh et al., 1999) , and additional cell cycle checkpoint functions are abrogated in certain human cancers (reviewed in McDonald and El-Deiry, 2001 ). In addition, DNA repair pathways also are also compromized in human tumors (reviewed in Khanna and Jackson, 2001 ). Cancer cells, however, not only have a decreased capacity to survey DNA damage due to checkpoint abnormalities and de®ciencies in DNA repair pathways, but they also have an intrinsic capacity to generate mutations (Nowell, 1976) .
Incubation of cells with the cytotoxic compound N-(phosphonoacetyl)-L-aspartate (PALA) can be used to assess the genomic stability of a cell population. PALA is an inhibitor of the aspartate transcarbamylase activity of the multifunctional protein containing activities for carbamoyl phosphate synthase, aspartate transcarbamylase, and dihydroorotase (CAD) enzyme and resistance to this compound is generated by ampli®cation of the CAD locus. In contrast to cancer-derived cells, normal human cells have a high degree of genomic stability and PALA resistant colonies arise at a very low frequency (Tlsty, 1990) . Expression of high-risk HPV E6 proteins in primary human cells dramatically increases the frequency of the emergence of PALA resistance. Analysis of PALA resistant colonies revealed that they exhibited ampli®-cation of the CAD locus. This likely re¯ects the loss of p53 function (Livingstone et al., 1992) . Interestingly, however, PALA resistant colonies also emerged from high-risk HPV E7 expressing cells, albeit at a lower frequency, and PALA resistance was generated by polyploidization (White et al., 1994) . This is consistent with other studies that show that E7 expressing cells are polyploid or aneuploid (Duensing et al., 2000; Hashida and Yasumoto, 1991; Southern et al., 2001) . Aneuploidy is generated by the gain or loss of chromosomes as a consequence of non-symmetrical chromosome segregation during cell division and is frequently observed in tumor cells (Figure 3) . The functional signi®cance of aneuploidy for tumorigenic progression is hotly contested in the literature. According to one model, aneuploidy is an early event that importantly contributes to carcinogenic progression whereas other investigators have argued that aneuploidization occurs as a late step and is a consequence of cell cycle dysfunction that is of limited functional signi®cance for tumorigenic progression (reviewed in Sen, 2000) . The delineation of the biochemical mechanism by which HPVs generate aneuploidy may shed some light on this important issue. Genomic instability and aneuploidy already occur in premalignant high-risk HPV-positive lesions (Heselmeyer et al., 1996) , and tripolar mitotic ®gures that can lead to abnormal chromosome segregation and aneuploidy are histopathological hallmarks of high risk HPV positive lesions (Figure 3) .
Several groups investigated whether E7 could interfere with mitotic processes. Whereas HPV E6, presumably through inactivation of p53, was able to eciently thwart multiple mitotic cell cycle checkpoints, these checkpoints retained a greater degree of functionality in E7 expressing cells (Thomas and Laimins, 1998; Thompson et al., 1997) . HPV E7 expressing keratinocytes eventually evaded the nocodazole-induced mitotic spindle assembly checkpoint and became polyploid, but this process was much slower than in HPV E6 expressing cells (Thomas and Laimins, 1998) .
Recent studies have shown that HPV-16 E7 can interfere with the ordered synthesis of centrosomes (Duensing et al., 2000 (Duensing et al., , 2001a . Centrosomes are major microtubule organizing centers and function as mitotic spindle pole bodies (reviewed in Murray, 2001) (Figure  3) . In normal cells, the duplication of centrosomes is tightly linked to the cell division cycle to ensure that they are duplicated once and only once per cell cycle (reviewed in Hinchclie and Sluder, 2001; Stearns, 2001) . Like many other tumors, high-risk HPVassociated precancerous lesions and cervical cancers contain abnormal centrosome numbers (Duensing et al., 2000; Skyldberg et al., 2001) . Centrosome abnormalities have been implicated in human carcinogenesis many years ago (Boveri, 1914) , but there has been considerable controversy whether centrosome abnormalities directly contribute to carcinogenic progression or whether they simply represent a manifestation of cells with genomic instability (summarized by Marx, 2001) . Studies with HPV E6 and/or E7 expressing cells have begun to illuminate this issue. Primary human keratinocyte populations with stable expression of HPV-16 E6 or E7 each contain abnormal centrosome numbers (Duensing et al., 2000) . Closer examination revealed that centrosome abnormalities in HPV E7 expressing cell populations occur in mononucleated cells and prior to chromosomal alterations (Duensing et al., 2001a) . Consistent with this result, transient expression of E7 in normal human keratinocytes rapidly yields numeric centrosome abnormalities (Duensing et al., 2000) , caused by increased synthesis of centrioles, the core subunits of centrosomes (Duensing et al., 2001a) . In contrast, HPV E6 expressing cells with abnormal centrosome numbers also display other manifestations of genomic instability, most notably multinucleization (Duensing et al., 2001a) . These results show that E6 and E7 expressing cells accumulate centrosome abnormalities through functionally distinct and complementing pathways. In Figure 3 Abnormal, tripolar mitotic ®gure in an HPV-associated squamous cell carcinoma (left) and schematic representation of centrosome abnormalities that can cause such defects which result in aberrant chromosome segregation and aneuploidy (right). HPV-16 E7 rapidly induces abnormal centrosome numbers. See text for details E7-expressing cells centrosome abnormalities are a driving force for genomic instability, while in E6 expressing cells they accumulate over time, in parallel with other manifestations of genomic instability (reviewed in Duensing and Munger, 2001) .
The ability of high-risk HPVs to induce aberrant centrosome duplication and induction of genomic instability is also observed in cells that contain HPV-16 episomes at a low copy number, suggesting that this activity is functional in premalignant lesions and contributes to carcinogenic progression by constantly generating cells with mitotic abnormalities (Duensing et al., 2001b) . Importantly, low risk HPV-6 E6 and E7 expressing cells do not accumulate centrosome abnormalities, thus correlating the ability of HPV E6 and E7 proteins to dysregulate centrosome homeostasis with malignant progression.
Concluding remarks
Over the years the HPV E7 protein has served as a remarkable tool to dissect cellular signal transduction pathways including proliferation, dierentiation and apoptosis. Perhaps most satisfying has been the ®nding that E7 and the integrity of the pRB binding site are indeed necessary for viral replication (Flores et al., 2000; Thomas et al., 1999) as has been postulated for many years. It also appears that high risk HPV E7 has developed a unique mechanism to interfere with the retinoblastoma tumor suppressor by inducing its proteolytic degradation and that this mechanism may be important for the functional inactivation of pRB. This has ®nally provided a molecular rationalization for how relatively low amounts of E7 can inactivate the pocket proteins that are quite abundantly expressed in many cells. The biochemical de®nition of the cellular components of this pathway remains an important challenge. In addition, there are indications that the carboxyl terminus of E7 speci®es an additional important determinant for cellular transformation. Even though a wide array of both nuclear and cytoplasmic proteins have been reported to interact with this region of E7, it remains to be determined which of these proteins represent functionally relevant cellular targets of E7. The ability of E7 to dramatically alter cellular metabolism, including glycolytic processes and intracellular pH regulation, may yield important insights as to how these processes are commonly dysregulated in human tumors. Last but not least, the ability of high-risk HPV E7 to rapidly induce centrosome abnormalities and increased genomic plasticity of the host cellular genome points to an important function of E7 as a mitotic mutator. This function of E7 may directly contribute to generating the host chromosomal changes that are necessary for carcinogenic progression of a high-risk HPV-positive precursor lesion. Whether uncoupling of centrosome duplication and cell division cycle has a positive impact on viral replication or whether it represents a cellular insult in¯icted as a consequence of viral replication, remains to be determined.
The low-risk and the high-risk HPVs are both highly successful viruses that infect similar tissues. The structures and presumably the functions of the highrisk and low-risk HPV E7 encoded proteins are quite similar. Thus it is rather surprising how many biological activities are NOT shared between the E7 proteins encoded by these two HPV classes. It is possible that the biological make-up of their respective target cells is dierent, and that these activities have evolved to maximize viral replication and persistence for each of these classes of viruses.
Another important aspect of the biology of HPVs is their ability to persist for many years. This is despite the fact that a squamous epithelium turns over at a very rapid rate. Both E6 and E7 have the capacity to delay keratinocyte dierentiation and it is tempting to speculate that E6 and/or E7 may have the capacity to retain some population of infected basal cells in a stemcell like state. Expression pro®ling of HPV expressing cells using genomics or proteomics approaches (Chang and Laimins, 2000; Hellung Schonning et al., 2000; Nees et al., 2000) may hold the answer to some of these important issues.
